Development of prognostic biomarkers using imaging of structural and metabolic heterogeneity in pancreatic ductal adenocarcinoma (PDAC) (C06)

• Subject Area: Nuclear Medicine, Radiotherapy, Radiobiology
• Term: from 2009 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618

Biomarker-based trial enrichment has so far not been implemented in PDAC. In the last funding period we developed a new PDAC classification system based on histological tumor cellularity and identified low baseline ADC values prognostic of poor overall survival. We will systematically continue and extrapolate this approach, hypothesizing that a close correlation of tumor biology (i.e. molecular, metabolic, physiologic data) and imaging data and complex statistical analyses of imaging data (i.e. machine learning) will improve the predictive value of imaging in PDAC.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Professor Dr. Rickmer Früdd Braren; Privatdozent Dr. Güralp Onur Ceyhan, until 12/2019; Professor Dr. Björn Menze